



Supplemental Table 1. Pathogenic and likely pathogenic variants in 113 unrelated index patients with LVNC 










ACTC1* NM_005159.4 c.301G>A p.E101K 4.061E-06 no P PS1, PS3, PS4 
ACTC1* NM_005159.4 c.301G>A p.E101K 4.061E-06 no P PS1, PS3, PS4 
ACTN2 NM_001103.2 c.574C>T p.R192* 8.122E-06 yes P PM2, PM6, PVS1 
HCN4 NM_005477.2 c.1445G>A p.G482E 0 no LP PM2, PM5, PS3 
HCN4 NM_005477.2 c.1454C>T p.A485V 7.217E-06 ? LP PP3, PM2, PS3 
MYBPC3 NM_000256.3 c.709T>C p.Y237H 0 ? P PM2, PS1, PS3 
MYBPC3* NM_000256.3 c.1484G>A p.R495Q 0.00002031 ? P PS1, PS3, PS4 
MYBPC3 ENSG00000134571 c.1805C>T p.T602I 9.848E-06 no LP PM2, PS1 
MYBPC3 NM_000256.3 c.2572A>C p.S858R 0 yes LP PM2, PM5, PS2 
MYBPC3* NM_000256.3 c.2864-2865delCT p.P955Rfs*95 0.00003232 ? P PS4, PVS1 
MYH7* NM_000257.2 c.715-717GACdel p.D239- 0 ? LP PM1, PM2, PS1 
MYH7* NM_000257.2 c.728G>A p.R243H 8.121E-06 no P PP1, PM1, PS1, PS4 
MYH7* NM_000257.2 c.754T>C p.F252L 0 ? LP PM1, PM2, PM5 
MYH7 NM_000257.2 c.847T>G p.Y283D 0 no LP PP3, PM1, PS4 
MYH7 NM_000257.2 c.1048T>A p.Y350N 0 yes LP PP3, PM1, PM2, PM6 
MYH7 ENSG00000092054 c.1283C>A p.A428D 0 no LP PP1, PP3, PM1, PM2 
MYH7 NM_000257.2 c.2770G>A p.E924K 0 no P PM1, PS1, PS4 
NEXN NM_144573.3 c.1876-1877Adel p.E626EX 0 ? LP PM2, PM4, PS3 






800N 0 ? LP 
PM1, PM2, PM4 
PRDM16 NM_022114.3 c.1573Cdel p.R525Pfs*79 0 yes P PS3, PS4, PVS1 
 2 
PRDM16 NM_022114.3 c.1627C>T p.Q543* 0 ? P PM2, PS3, PVS1 
PRDM16 NM_022114.3 c.2104A>T p.K702* 0 yes P PS3, PS4, PVS1 
RAF1 NM_002880.3 c.806C>T p.T269I 0 ? LP PP3, PM2, PS3 
RBM20 NM_001134363.1 c.2737G>A p.E913K 0 no P PS1, PS3, PS4 
TAZ NM_000116.3 c.355G>A p.V119M 0 no LP PM1, PM2, PM5 
TNNI3 NM_000363.4 c.428C>A p.T143N 0.00004071 ? LP PM1, PS4 
TNNT2* NM_000364.2 c.421C>T p.R141W 0 yes P PS1, PS3, PS4 
TNNT2 NM_001276345.1 c.460C>T p.R154W 0.00003676 ? P PM2, PS1, PS3 
TPM1 NM_001018005.1 c.257C>T p.A86V 0 no LP PP1, PP3, PM1, PM2 
TPM1* NM_001018004.1 c.574G>A p.E192K 0 ? P PS1, PS4 
TTN NM_001267550.1 c.4714C>T p.R1572* 0 no LP PM1, PM2, PM4 
TTN NM_001267550.1 c.4724_4728delTGAAA p.M1575Sfs*6 0.00001084 ? LP 
PM1, PM2, PM4 
TTN NM_001267550.1 c.63601C>T p.R21201* 0.00001089 ? LP PM1, PM2, PS1 
TTN NM_001267550.1 c.63601C>T p.R21201* 0.00001089 ? LP PM1, PM2, PS1 
TTN NM_001267550.1 c.70879C>T p.Q23627* 0 ? LP PM1, PM2, PM4 
TTN NM_001267550.1 103360 p.E34454Nfs*3 0.0000217 ? LP PM1, PM2, PM4 
TTN NM_001267550.1 c.103360Gdel p.E34454X 0.0000217 ? LP PM1, PM2, PS1 
TTN NM_001267550.1 c.107284C>T p.R35762* 0 ? LP PM1, PM2, PM4 
 
*Previously published variants (Sanger sequencing of 8 genes) in Probst et al. (PMID: 21551322). 
LP = Likely pathogenic; P = Pathogenic; VUS = Variant of uncertain significance   
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<18 years at 
diagnosis 
n=43 
>18 years at 
diagnosis 
n=66 
Patients with 0 variants 25 (23) 11 (26) 14 (21) 
Patients with 1 variant 51 (47) 19 (44) 32 (49) 
Patients with 2 variants 22 (20) 10 (23) 12 (18) 
Patients with ≥3 variants 11 (10) 3 (7) 8 (12) 
Patients with VUS only 49 (45) 20 (47) 29 (44) 
Patients with (likely) pathogenic 
variant only 18 (17) 5 (12) 13 (20) 
Patients with VUS and (likely) 
pathogenic variants 17 (16) 7 (16) 10 (15) 
Total variants, n 130 48 82 
Total VUS, n 92 34 58 
Total likely pathogenic variants, n 24 9 15 
Total pathogenic variants, n 14 5 9 
Values are given as n (%). 
Abbreviations: VUS = Variant of uncertain significance   
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Female 54 (39) 26 (47) 28 (34) 0.123 
Age at diagnosis (yrs) 27.8 (9.2-44.7) 1.9 (0.2-10.7) 40.3 (29.0-54.1) <0.001 





Symptomatic 68 (55) 17 (34) 51 (69) <0.001 
Congenital heart defect 23 (17) 13 (24) 10 (12) 0.079 
Ventricular septal defect 11 (8) 8 (15) 3 (4) 0.027 
Patent foramen ovale 10 (7) 7 (13) 3 (4) 0.089 
Ebstein anomaly 5 (4) 2 (4) 3 (4) 1.000 
Patent ductus arteriosus 4 (3) 4 (7) 0 (0) 0.024 
Other congenital heart 
defects 
4 (3) 1 (2) 3 (4) 0.649 
Echocardiography     
  Reduced LV systolic   
  function 61 (46) 17 (33) 44 (55) 0.012 





  Increased LVEDD 55 (45) 21 (45) 34 (45) 0.944 





  LVEDD (Z-score)  1.66 (0.40-4.39)   
  Increased LVEDD and  
  reduced LV systolic function 
39 (33) 11 (24) 28 (38) 0.113 
Subtypes    
<0.001 
  LVNC 45 (46) 13 (33) 32 (54) 
  Dilated LVNC 32 (32) 10 (25) 22 (37) 
  Hypertrophic LVNC 22 (22) 17 (43) 5 (9) 
ECG     
  ST-Depression 20 (15) 3 (5) 17 (21) 0.013 
  T-Inversion 22 (16) 5 (9) 17 (21) 0.069 
  Bundle branch block 21 (19) 2 (5) 19 (28) 0.002 
  Arrhythmias 25 (18) 5 (9) 20 (24) 0.007 
   Atrial fibrillation 2 (2) 0 (0) 2 (2) 0.516 
   Atrioventricular block II°/III° 1 (1) 1 (2) 0 (0) 1.000 
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Values are given as n (%) or median (interquartile range). 
Abbreviations: HTx = Heart transplantation, ICD = Implantable cardioverter defibrillator, LVEDD 
= Left ventricular end-diastolic diameter, LV = Left ventricular, LVNC = Left ventricular 
noncompaction cardiomyopathy, LV-EF = Left ventricular ejection fraction, MACE = Major adverse 
cardiac events 
   Supraventricular tachycardia 8 (6) 2 (4) 6 (7) 0.475 
   Ventricular tachycardia 17 (12) 4 (7) 13 (16) 0.135 
ICD 24 (18) 2 (4) 22 (27) <0.001 
Follow-up (yrs) 5.6 (1.8-11.4) 3.5 (1.5-7.4) 7.8 (1.8-13.7) 0.016 
Complications     
  MACE 27 (20) 12 (22) 15 (18) 0.611 
  HTx 14 (10) 9 (16) 5 (6) 0.052 
  Death 11 (8) 2 (4) 9 (11) 0.121 
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Supplemental Table 4 
Hazard ratio – Risk for MACE – univariate  
 all <18 years at diagnosis >18 years at diagnosis 
 HR (95% CI) P-Value HR (95% CI) 
P-
Value HR (95% CI) P-Value 
Age at diagnosis 




area (m2) 0.51 (0.27-0.97) 0.039 0.16 (0.03-0.97) 0.047 
0.41 (0.05-
3.33) 0.404 
LV-EF (%) 0.94 (0.92-0.97) <0.001 0.92 (0.87-0.96) 0.001 0.96 (0.93-1.00) 0.036 
Increased 





LVEDD (mm) - - - - 1.05 (1.00-1.10) 0.032 
LVEDD (Z-





3.78 (1.44-9.96) 0.007 11.97 (1.39-103.22) 0.024 
2.82 )0.94-
8.43) 0.064 





Arrhythmias 2.03 (0.86-4.79) 0.108 1.37 (0.25-7.50) 0.718 2.19 (0.78-6.19) 0.138 
Abbreviations: LVEDD = Left ventricular end-diastolic diameter, LV = Left ventricular, LV-EF = 
Left ventricular ejection fraction, MACE = Major adverse cardiac events 
 
 
Supplemental Table 5 
Hazard ratio – Risk for MACE – multivariate  
 all <18 years at diagnosis >18 years at diagnosis 
 HR (95% CI) P-Value HR (95% CI) 
P-




diagnosis (yrs) - - - - 1.04 (0.996-1.08) 0.076 
Body surface 
area (m2) 0.36 (0.15-0.88) 0.026 0.03 (0.00-2.95) 0.130 - - 
LV-EF (%) 0.94 (0.91-0.98) 0.003 0.92 (0.86-0.99) 0.032 0.96 (0.91-1.02) 0.165 
Increased 
LVEDD  0.75 (0.22-2.52) 0.643 - - - - 
LVEDD (mm) - - - - 0.996 (0.93-1.06) 0.914 
LVEDD (Z-
score) - - 1.37 (0.90-2.09) 0.148 - - 
Symptomatic 3.03 (0.71-12.88) 0.133 - - - - 
Dashes (-) indicate variables that were not included in multivariate analysis. 
Abbreviations: LVEDD = Left ventricular end-diastolic diameter, LV-EF = Left ventricular ejection 
fraction, MACE = Major adverse cardiac events 
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Kaplan-Meier analysis for event-free survival time between the LVNC subtypes. The combined 
endpoint are major adverse cardiac events (mechanical circulatory support, heart transplantation, 
survived sudden cardiac death and/or all-cause death). 
